… ) trial, which investigated the efficacy of bivalirudin in this patient population is the main
focus of this section.[10,37,38] In both of these trials, bivalirudin was administered as a 0.75 mg/…

… The higher cost of bivalirudin may be offset if it reduces costly bleeding complications and/…
of using bivalirudin on the costs of care among patients with ST-segment elevation myocardial …

… patients with ST-segment elevation myocardial infarction (STEMI) were randomized during
transport for primary PCI to bivalirudin … analysis compared patients receiving bivalirudin (n = …

… In this prespecified separately powered subgroup analysis, we included patients with ST-segment–elevation
MI undergoing primary percutaneous coronary intervention with the primary …

… a full dose post PCI bivalirudin infusion in order to determine whether bivalirudin should
become the first choice anticoagulant during primary PCI in all patients with STEMI worldwide. …

… In the largest comparative analysis of bivalirudin versus UFH for non–ST-segment–elevation
myocardial infarction to date, bivalirudin was associated with lower in-hospital bleeding …

… This review focuses on the safety and tolerability of bivalirudin in adult patients in the setting
of currently approved indications. It focuses more specifically on bleeding complications to …

… The optimal anti-coagulation strategy for patients with non-ST-elevation myocardial
infarction … whether bivalirudin was superior to heparin monotherapy in patients with non-ST-elevation …

… The purpose of our study is to compare bivalirudin versus heparin monotherapy in ACS
patients undergoing PCI with pretreatment with ticagrelor, prasugrel, or cangrelor in the radial …

Background Previous randomised trials of bivalirudin versus heparin in patients with ST-segment
elevation myocardial infarction (STEMI) undergoing primary percutaneous coronary …